Skip to content

    Multiple Sclerosis Health Center

    Font Size
    A
    A
    A

    Don't Delay MS Treatment

    Brain Creates New Lesions When Drug Therapy Delayed
    By
    WebMD Health News

    Oct. 25, 2002 -- For people with multiple sclerosis (MS), a delay in treatment allows the disease to worsen.

    A new study looks at treatment for relapsing-remitting MS, a form of the neurological disorder that involves acute attacks followed by recovery periods.

    Those patients who didn't start drug therapy immediately -- who waited nine months after diagnosis -- accumulated new lesions in their brains, writes researcher Jerry S. Wolinsky, MD, director of the MS Research Group at the University of Texas Health Sciences Center in Houston.

    His study appears in this month's edition of Neurology.

    In his 18-month study, Wolinsky randomly assigned 224 MS patients to receive either the drug Copaxone or a placebo soon after diagnosis for the following nine months. Then all patients were given the active drug for the next nine months.

    Teva Pharmaceuticals, the makers of Copaxone, supported this work.

    "Over the entire 18 months of the study there were 35% fewer enhancing lesions among the patients who started drug therapy early," he says in a news release.

    His study also finds that the group of patients receiving drug therapy continuously had 23% fewer relapses compared with the group who started active treatment nine months later. -->

    Today on WebMD

    nerve damage
    Learn how this disease affects the nervous system.
    woman applying lotion
    Ideas on how to boost your mood and self-esteem.
     
    woman pondering
    Get personalized treatment options.
    man with hand over eye
    Be on the lookout for these symptoms.
     
    brain scan
    ARTICLE
    worried woman
    ARTICLE
     
    neural fiber
    ARTICLE
    white blood cells
    VIDEO
     
    sunlight in hands
    ARTICLE
    marijuana plant
    ARTICLE
     
    muscle spasm
    ARTICLE
    Neuron
    ARTICLE